Cubosomes for rheumatoid arthritis: enhancing anti-inflammatory drug delivery

Inflammation is a type of defence mechanism employed by the immune system that hinders infection advancement and supports the effective elimination of a variety of external invasions. Self-assembled nanostructures, particularly cubosomes are gaining increased utility and popularity as a medication transport mechanism under circumstances like arthritis. These cubosomes serve as highly adaptable carriers with encouraging theranostic capabilities and can be delivered through oral, topical, intravenous, ocular, and transdermal routes. Recently valuable research has contributed to enhancing the effectiveness, analysis, target specificity, and regulation of drug release profiles for delivery of anti-inflammatory bioactive. However, the clinical transition has been sluggish and also necessitates substantial display. This review highlights the late developments with challenges in the progress as well as appeal of cubosomes in case of different inflammatory pathways on rheumatoid arthritis while also addressing the obstacles encountered in transforming it into a viable nanotechnological solution.